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Abstract

INVESTIGATING THE EFFECT OF NUCLEOSOME REMODELING FACTOR
KNOCKDOWN ON ANTI-TUMOR IMMUNITY
by Mark G. Roberts, B.S.

A thesis submitted in partial fulfillment of the requirement for the degree
Master of Science at Virginia Commonwealth University
Virginia Commonwealth University, 2016
Major Director: Joseph Landry, PhD
Assistant Professor
Department of Human and Molecular Genetics

The nucleosome remodeling factor (NURF) is a chromatin remodeling complex
involved in early animal development and is implicated in a number of cancers. In
previous work, knockdown of NURF’s largest subunit, BPTF, resulted in diminished
tumor growth in mouse cancer cell lines. Other studies in our lab demonstrated
increased activation of T-lymphocytes into BPTF KD tumors. In order to examine if this
approach has any therapeutic potential, this work investigates the effects of BPTF
knockdown in established tumors by using recombinant adenoviruses (rAd), as well as
observe the way the immune system interacts with BPTF knockdown cells, both in vivo
by flow cytometry and in culture with cytotoxicity assays.

ix

Chapter 1: Introduction
Immunoediting of Cancer Cells

Immunoediting is the phrase used to describe the role that the immune system
plays in the initial prevention and later shaping (“editing”) the immunogenic features of
neoplastic cells (Dunn, 2004). Immunoediting is comprised of three parts: elimination,
equilibrium, and escape.
During elimination, emerging cancer cells which have acquired new mutations
that lend a proliferative advantage are killed in a similar manner to that of foreign
pathogens. Incomplete elimination results in inactive tumor cells or cancer cells which
are changing their immunogenicity to survive, such as altering surface antigens. This
dormant phase in tumorigenesis is the second part of immunoediting, known as
equilibrium. In equilibrium, tumor cells are selected by the immune system with some
cells being killed and others changing their antigenic profiles to survive. Eventually,
some of the cells that survive gain enough of an immunological advantage to move on
to the final phase of immunoediting. During the final phase of immunoediting, the
escape phase, a tumor begins to form. Note that at all three steps, a failure of the
immune system to recognize tumor cells is required to move on to the next stage
(Swann 2007).
In the last 20 years there has been a surge of interest in the role of lymphocytes
in tumor development. When researchers showed that tumors in mice treated with
monoclonal antibodies for IFN gamma (IFN- γ) grew faster (Dighe et al, 1994) and that
mice without competent immune cells formed tumors more than controls, scientists

began looking at the role of the immune system in cancer. Since then, two types of
lymphocytes have been found at the frontline of the human body’s battle with cancer: Tcells and NK cells.

T-cells and NK cells: Tumor Infiltrating Lymphocytes

Lymphocytes, commonly known as white blood cells, are so called because they
are found in the lymph nodes and lymphatic system, a filtration system of the blood.
They include NK cells, B-cells, and T-cells. Although there is a subset of B cells (CD20+
B-cells) that have been shown to infiltrate tumors (Nelson, 2010), the focus of this thesis
will be on the better characterized TILs of NK and T-cells.
T-cells are a part of the adaptive or acquired immune system. Originating in the
bone marrow from hematopoietic stem cells (Shortman and Wu, 1996), they mature in
the thymus, where they are exposed to antigens presented by the major
histocompatibility complex (MHC). The function of the MHC is to take fragments of
foreign pathogens that have been killed by professional phagocytes and present them
on the cell surface to T-cells (Janeway 2001). Once in the thymus, T-cells are selected
for their affinity for either MHC class I or II. MHC I is found on all nucleated cells, and
typically presents cytosolic or viral peptide fragments from infected or stressed cells
(such as tumor cells) to cytotoxic T-cells to elicit a response (Tortorella et al, 2000).
MHC class II typically presents extracellular antigens such as cell surface proteins or
soluble antigens (Cresswell, 1994). T-cells which bind MHC I with high affinity express a
an MHC class I restricted TCR along with a co-receptor known as CD8, which is needed
2

to activate the cell in the presence of an MHC-I antigen (Rudolph et al 2006). T-cells
which bind MHC II express CD4, and are known as helper T-cells, due to their role in
activating other effector cells such as B-cells, rather than displaying their own cytolytic
activity (Mosman et al 1986, Zhu et al 2008).
CD8+ CTLs operate by recognizing antigens presented by MHC I, which binds to
their TCR. At the same time, CD8 binds the MHC I molecule itself (Janeway 1992.)
Following MHC/CD8 binding, a second stimulatory molecule, such as B7, binds to either
CD28 or CTLA-4 on the CTL cell surface. This second step leads to activation of the
antigen-specific T-cell, which expands in a clonal manner to address the antigen
presented to it (Kolumam et al 2005). In the absence of these stimulatory signals, Tcells die and a few memory cells remain in an anergic state, in case the antigen should
be encountered again (Williams & Bevan, 2006).
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Figure 1. A cartoon representation of the 2 signal process of T-cell activation. A) A
professional antigen presenting cell brings antigenic fragments via MHC to a T-cell. As the MHC
binds the TCR, co-stimulatory CD80 on the APC binds CD28, leading to activation. B) Lack of
the second signal from binding of CD28 leads to anergy of the T-cell. (Harber et al. 2000).

NK cells belong to the innate or passive immune system. They were originally
named “natural” killer cells due to their observed ability to kill targets without antigen
driven priming, as seen in T-cells (Caligiuri, 2008). NK cells are covered with activating
and inhibitory receptors, and the status of the cell’s activation is determined by the ratio
of those receptors being bound (Moretta et al, 2001). Essentially this means that when
there are more activating receptors than inhibitory receptors bound, then NK cells will
kill the target. NK cells kill by what’s known as “the missing self hypothesis”(Kärre et al,
1986). NK cells are inhibited when they come in contact with self-MHC class I, sparing
healthy cells with normal levels of MHC I on their surface. When they come in contact
4

with a cell with activating ligands (for instance, MICA on tumors (Bauer et al, 1999)) that
do not express the inhibitory MHC I, they kill the cell by releasing perforin and
granzyme, lysing the cells (Smythe et al,1999). An example of NK cell activation by
tumor cells is provided in Figure 2.

Figure 2. Cartoon representation showing three modes of NK cell activity: a.) in the case
of healthy cells, NK cells will recognize their MHC class I on the surface, causing inhibition. b.)
In tumor cells, MHC I is sometimes lost, which triggers activation of the NK cell due to the lack
of binding to inhibitory receptors (“missing self hypothesis”). c.) Finally a tumor cell can present
stress-induced proteins and glycoproteins on the surface, which NK cells recognize and are
activated by to kill the tumor cell. (Vivier et al, 2012).

Both NK cells and CTL’s are known to infiltrate tumors (Coca et al, 1997,
Ishigami et al 2000, Naito et al 1998). In fact, in mice which lacked NK cells, tumors
5

grew more rapidly and aggressively (Dunn et al 2004, Gorelik et al 1982). Additionally,
increased infiltration is a good indicator for survival (Coca et al, Ishigami et al, Gooden
et al, 2011).

Immunotherapy

Immunotherapy is a developing field of cancer treatments (cancer.org). Its goal is
either to enhance or suppress an immune response, resulting in a reduction of tumor
growth. Given the role the immune system is understood to play in the immunoediting of
tumor cells, this represents a significant opportunity for the exploration of new
therapeutics for cancer.
Currently, there are a number of FDA-approved monoclonal antibody drugs to
treat cancer. These drugs bind to antigens present on the surface of cancer cells,
allowing them to be recognized by either cytotoxic T cells or B cells and are
subsequently killed (Scott et al, 2012). Another approach which is currently being
investigated is known as chimeric antigen receptor therapy (CAR-T). In this treatment,
blood is taken from the patient and his or her lymphocytes, specifically T-cells are
isolated. These then are given receptors specific to the patient’s cancer, and then
reintroduced into the blood of the patient. These new chimeric T-cells are able to
recognize and kill the tumor cells in the patient (Porter et al, 2011).
More recently, targeted NK cells, “taNKs” are being developed for more
individualized cancer treatments (Klinngemann et al, 2016). These cells, like their CART cousins, would be given receptors for an antigen found on the surface of a patient’s
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tumor cells. Given the ability to easily transfect NK cells and grow them, this is an
exciting development.

Epigenetics

Epigenetics, which means “above the gene”, is the process which changes
expression of genes in a heritable manner but without changing the basic genomic DNA
sequence (Dupont, 2009). Epigenetic mechanisms are crucial during embryogenesis (Li
et al, 1992), X-chromosome inactivation (Brinkman, 2006), and is also involved in
imprinted gene disorders such as Prader Willi and Angelman’s Syndromes (Ohta et al,
1999). Abnormal epigenetic function leading to altered gene expression has been found
almost universally in cancer (Sharma et al 2010).
There are four common epigenetic modifications to DNA: DNA methylation,
modifications to histones, RNA interference, and chromatin remodeling (Kim et al, 2009,
Grewal & Moazed 2003).

Chromatin Remodeling Complexes

DNA, which encodes the instructions for life, is roughly six billion base pairs long
in humans. When linearized this is roughly six feet of DNA inside each cell. In order for
it to fit within the nucleus it must be condensed by proteins called histones. This DNAprotein complex is known as chromatin (Fig. 3). Chromatin is divided into two classes:
open and accessible euchromatin, and closed and inacessible heterochromatin.
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The basic unit of chromatin is a histone. Histones are made of four pairs of
histone proteins to form an octamer. Around each histone octamer are 147 base pairs
of DNA (Luger et al, 1997). The full histone octamer and DNA complex is known as a
nucleosome. When coiled around the histone octamer, DNA is not accessible and thus
cannot be transcribed. To get around this problem, the cells has proteins known as
chromatin remodelers, whose main purpose is to use the energy from ATP hydrolysis to
move the nucleosome around to make the DNA accessible to transcription activating
factors (Vignali et al, 2000, Kornberg et al 1999). As a result, chromatin remodelers are
intrinsically tied to the process of gene regulation.

Figure 3. A cartoon representation of the packaging of DNA into chromatin in the nucleus
of the cell. DNA is wrapped around a histone octamer to form a nucleosome, which is further
condensed into 30 nm chromatin fibers, which ultimately forms chromosomes and is packed into
the nucleus. (Meshore et al, 2010).
8

There are four main classes of ATP driven chromatin remodelers: SWI/SNF,
ISWI, CHD and INO80. The SWI/SNF (or switch/sucrose non-fermentable) family is
able to slide the nucleosome or evict it from the DNA entirely (Priya Sudarsanam, 2000).
ISWI (imitation switch) is similar to SWI/SNF in that it also slides the nucleosome, but
does not evict it. The CHD (chromodomain) class of remodelers can slide or eject
nucleosomes, while other CHD remodelers have been known to repress transcription by
interacting with deacetylase enzymes to condense chromatin (Clapier 2008). Finally, the
INO80 (inositol requiring 80) group is defined by a split ATPase domain, and are known
for removing and replacing two histone proteins to remodel the nucleosome (Clapier
2008). A summary of these mechanisms can be seen in Figure 4.

Figure 4. Chromatin remodeling complexes, which modify the position of nucleosomes
to make accessible the DNA they contain, display 4 main modes of ATP-dependent
remodeling. ATP is hydrolyzed and ADP is released creating energy for the remodeling
complex to: slide the nucleosome as seen in SWI/SNF, ISWI and CHD remodelers, unwrap
DNA from the nucleosome, evict histones as seen in SWI/SNF and INO80, and exchange
histone variants which has been observed INO80 (Xu et al, 2013).
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Nucleosome Remodeling Factor (NURF)

The nucleosome remodeling factor, or NURF (Fig. 5) , is a member of the ISWI
family. Composed of BPTF (bromodomain PHD finger transcription factor), an ATPase
subunit SNF2L, and pRBAP46/48 subunits in mammals (Barak et al 2003). NURF slides
nucleosomes bi-directionally in 10 base pair intervals (Schwanbeck 2004). The PHD
finger binds H3K4me3, while the bromodomain has been found to bind H4K16ac. Both
of these modified histones are associated with active transcription sites (Zhang et al
2015, Gelbart et al 2009, Taylor et al 2013).
In Drosophila, where it was first characterized, NURF is involved in
embryogenesis. Specifically, the gene Ubx, which aids in the development of the thorax,
abdomen and wings, requires NURF for transcription (Badenhorst, 2002). In D.
melanogaster, mutants for NURF301 (the homolog to human BPTF) exhibit abnormal
expression of heat shock, JAK/STAT, and homeobox genes (Badenhorst 2002,
Badenhorst 2005, Kwon 2008). In mice, BPTF knockout mice fail to gastrulate, due to
the need for BPTF by embryonic mouse stem cells for mesoderm and endoderm
differentiation (Landry et al 2008). BPTF is involved in thymocyte development in both
mice and humans, (Landry et al, 2011).
In humans, BPTF is located on the distal arm of chromosome 17q24.3 (Jones et
al, 1999). This region has been found to be amplified in a number of neoplastic tissues,
including liver, lung, brain, prostate, bladder and breast cancers (Buganim et al, 2010.
Kallioniemi et al, 1994, Choi et al, 2006, Sun et al 2008, Raidl et al 2003). These
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amplifications suggest BPTF may play a role in the development of tumors. Knockdown
of BPTF in mouse melanoma tumors led to a significant reduction in tumor growth in a
study by Dar et al. Additionally, BPTF has recently been shown to associate with cMyc, a well-known oncogene found in a diverse array of cancer types (Richart, 2016).
Finally, high BPTF expression in lung cancer and hepatocellular carcinoma is linked to
poor survival (Xiao et al, 2014, Dai et al, 2015). For these reasons, it is a target for
investigation, as these studies indicate a causal relationship between BPTF and
tumorigenesis.
`

Figure 5. The components of NURF as seen in humans. BPTF, the largest subunit is
essential for the function of NURF. SNF2L is the human homolog to the Drosophila ISWI, and
RBAP46/48, a WD repeat protein (Alkhatib & Landry, 2011).

Adenovirus
Human adenoviruses are DNA viruses, and are nearly ubiquitous in humans.
Belonging to the genus Mastadenovirus (Davison et al, 2003), there are 51 recognized
serotypes. Upon infection of the host cell, adenoviruses quickly begin the process of
11

transcribing their early genes, E1-E4. These genes encode viral replication proteins as
well as some virulence factors needed for evasion of the host immune response.
Recombinant adenoviruses can be made from kits that come with strains ready
made for insertion of a given DNA sequence (Fig. 6) . Most strains provided have
deleted E1 and E3 sites. Deletion of E1 genes allows not only for substitution with
desired transcripts (up to roughly 8 kilobases), but also renders the virus replication
deficient. As such it can only grow in cells which contain E1 genes, for example, HEK
293 cells. Deletion of E3 genes, as has become more common in addition to E1 deleted
genomes, results in a virus that is devoid of proteins which are normally used for
evasion of the immune response (He et al, 1998).
Adenoviruses are advantageous as vectors because of their large cassette
capacity, their ability to infect a wide range of cell types, and because of their extremely
high delivery efficiency, which approaches 100% (Wagner et al, 1992). Finally, and
perhaps most importantly, adenoviruses do not integrate their genome into that of the
host (Salahuddin, 2011). This is crucial from a gene therapy perspective because this
means there will be no disruption of host DNA, which has been known to lead to
uncontrolled cell proliferation if the disrupted gene in question is one that regulates the
cell cycle (Hacien-Bey-Abina et al, 2003).
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Figure 6. A cartoon representation of the lifecycle of a recombinant adenovirus. A
recombinant adenovirus contains a desired gene flanked by the adenovirus genome and its
associated promoters and inverted terminal repeat (ITR) regions, which promote transcription.
In a complementary cell, the host provides the E1 genes needed for replication to produce
recombinant virus. When the virus infects a target cell lacking E1, the result is expression of the
inserted gene but without viral replication (Salahuddin, 2011).
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Previous Work in the Landry Lab and Rationale for Study

Previous work in the Landry lab originally focused on studying tumor growth upon
KD of BPTF by short hairpin RNA via retrovirus. It was found that KD inhibited tumor
growth in syngeneic implanted tumors, but did not affect doubling times in culture (Fig.
7-8, currently under revision for Cancer Research). This suggested that the BPTF KD
cells were likely not killed directly by BPTF KD, as viability was not affected. Rather, it
was hypothesized that the immune system mediated the reduced growth of the tumors.

Figure 7. BPTF KD in multiple cell lines reduces tumor cell growth. The murine breast
cancer lines 4T1, 67NR, and 66CL4 were treated either with control or BPTF short hairpins and
implanted into BALB/C mice. A mouse melanoma line, B16F10, was also was used in
syngeneic C57BL/6 mice to asses effects of BPTF KD on tumor growth. Tumor weights in the
KD lines were significantly reduced compared to controls.
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Figure 8. Doubling times of multiple tumor cell lines unaffected by BPTF KD. BPTF KD

and control cells of mouse cell lines B16F10, 4T1, 67NR and 66CL4 were plated and were
counted at 24, 48 and 74 hours to calculate doubling time. No significant change in
doubling time was observed between KD and controls.

To test whether the immune system mediated tumor reduction, two approaches
were used. First, control and KD tumors would be implanted in NSG mice. NSG mice
lack B cells, T cells, and NK cells. Tumors grown in NSG mouse had no significant
difference in size (Fig. 9). Next, the type of lymphocyte responsible for the reduced
growth was sought. Monoclonal antibodies were used to deplete CD4+ T-cells, CD8+ Tcells, and NK cells. These depletion studies showed that cytotoxic CD8+ T-cells (CTL)
were likely responsible for reduced tumor size in 4T1 and B16F10 tumors (Fig. 10), and
15

that NK cells were responsible in 66CL4 and 67NR cells (Fig. 11).

Figure 9. Tumor weight in 4T1, 67NR and 66CL4 control and KD tumors in NSG
mice. Murine breast cancer lines 4T1, 66CL4 and 67NR, as well as a mouse melanoma line,
B16F10, were treated with either control of BPTF KD shRNA. When these lines were
transplanted into NSG mice lacking major immune system components, tumors showed no
difference in weight between KD and control in all three lines, indicating an immune system
involvement.
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Figure 10. Monoclonal antibody depletion of lymphocytes identifies T-cells as important
for enhanced anti-tumor immunity to BPTF KD in 4T1 and B16F10 tumors. Mice with 4T1
(A) and B16F10 (B) tumors were treated with monoclonal antibodies for CD4, CD8 and AsialoGM1 to deplete helper T-cells, cytotoxic T-lymphocytes, and NK cells respectively. The results
show no observable difference in tumor weights between no depletion and NK cell (anti-AsialoGM1) depletion. Depletion of T-cells resulted in a rescue of tumor weights between controls and
BPTF KD, indicating a role of T cells in BPTF KD mediated tumor inhibition.
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Figure 11. Monoclonal antibody depletion of lymphocytes identifies NK cells as
important for enhanced anti-tumor immunity to BPTF KD in 66CL4 and 67NR. Control and
BPTF KD tumors of 66CL4 and 67NR mouse breast cancer lines were treated with antibodies
specific for CD4, CD8, and Asialo-GM1, an NK cell surface molecule and tumor weights were
assessed. Anti-asialo-GM1 antibody depletion of NK cells in 67NR and 66CL4 demonstrated a
rescue of tumor weight in BPTF KD.

To address whether or not CTLs were actually infiltrating BPTF KD tumors in
greater numbers, flow cytometry was used to count and characterize CD8+ T-cells
within 4T1 and B16F10 tumors. Upon assaying the tumors, it was found that T-cells in
KD tumors were not only more numerous, but more active as well (Fig. 12). This effect
was not seen in the spleen, however, which suggested that indeed there was an
immunogenic component to the KD tumors themselves.
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Figure 12. Increased infiltration and activation of CTLs seen in BPTF KD tumors but not
spleen of mice with 4T1 and B16F10 lines. 4T1 and B16F10 control and BPTF KD tumors
were assessed by flow cytometry. A) Anti-TCRb and anti-CD8 antibodies were used to select
cytotoxic T-lymphocyte population in order to quantify level of infiltration. B) Percent of
lymphocytes which were positive for CD8 and TCRb (CTLs) were compared between spleens
and tumor populations in 4T1 and B16F10. C) Anti-CD8 and anti-CD69 antibodies allow for
quantification of activation in CD8 positive cells. D.) Percentages of active CD8 cells were
compared in spleen vs tumor populations, with significant increase in activation found in the
tumors of both 4T1 and B16F10 BPTF KD, but not spleens.
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These results suggest that: 1.) BPTF KD results in the upregulation of a
stimulatory molecule or the downregulation of an inhibitory antigen on the surface of the
cell, inducing an immune response, 2.) this immune response is mediated by NK and Tcells, 3.) BPTF KD results in an increase in anti-tumor activity. From this, we
hypothesize that 1.) BPTF KD in established tumors will have a similar effect as seen in
syngeneic KD tumors, thereby imitating a therapeutic agent, and 2.) NK cells will be
more active and preferentially kill BPTF KD cells in vitro and in vivo.

20

Specific Aims

Aim 1: To determine whether KD of BPTF using recombinant adenoviruses will result in
reduced growth of established tumors.
Hypothesis: Knockdown of BPTF in established tumors will result in reduced tumor
growth compared to controls.

Aim 2: To characterize NK cell infiltration and activation in 66CL4 and 67NR
knockdown tumors in comparison to controls.
Hypothesis: NK cell infiltration and activation will be greater in BPTF KD tumors.

Aim 3: To determine if BPTF KD renders human breast cancer cells more susceptible
to NK cell cytotoxicity in vivo.
Hypothesis: BPTF KD human cancer cell lines will be more susceptible to human NK-92
cytotoxicity.

21

Chapter 2: Methods and Materials

Cell Culture

4T1, 66CL4, and 67NR tumor lines were all grown in DMEM supplemented with
10% FBS, 1X non-essential amino acids (NEAA), 2mM glutamine, 100 units/mL of
penicillin and 100mcg /mL of streptomycin at 37˚C and 5% CO2. For the purpose of
growing tumors for analysis by flow cytometry, confluent cells were counted and diluted
to the following cell counts: 6 x 106 cells/mL for 4T1, 2 x 106 cell/mL for 67NR, and 2 x
105 cells/mL for 66CL4. These dilutions would be used to transplant the tumors into
mice. The tumors would grow for 3 weeks for 67NR flow cytometry purposes, 4 weeks
for 66CL4 for flow cytometry, and 7-10 days for 4T1 adenoviral experiments, or
whenever first palpable.
Previously retrovirus treated BPTF knock down human tumor cell lines T47D and
MDA-MB-436 were grown in DMEM supplemented with 10% FBS, 1X NEAA, 2 mM
glutamine, 100 units/mL of penicillin, 100 mcg/mL of streptomycin, 10mcg/mL bovine
insulin, and 5 mg/5 mL puromycin at 37˚C and 5% CO2.
NK-92 cells, an immortalized line of human natural killer cells, were used in the
LDH assay to assess killing in BPTF knockdown human cancer cell lines. NK-92 cells
were grown in Alpha Minimum Essential Media (Alpha MEM) without ribonucleosides or
deoxynucleosides, supplemented with 12.5% FBS, 12.5% horse serum, 1.5 grams
sodium bicarbonate/L, 0.2mM inositol, 0.1mM beta mercaptoethanol, .02mM folic acid,
100 units/mL penicillin, 100mcg/mL streptomycin, and 200 Units/mL of IL-2.
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Creation of rAd Containing Control or BPTF shRNAs

Using plasmid pE1.2 (containing the early 1 gene backbone for adenovirus)
cloned with either BPTF knockdown short hairpin (shRNA) 28 or a shRNA to luciferase,
pE1.2 plus insert was digested with DraIII restriction enzyme, as was pE3.1. The 300
base pair fragment from pE3.1 (Early 3 gene backbone) and the 1.8kb fragment from
pE1.2 were then gel purified using by ethanol precipitation. These were then ligated with
pAd388, which contained the adenovirus genes, using T4 ligase. Ligation mixture was
incubated at 16 degrees Celsius overnight.
To package this ligation into competent bacteria, the Gigapack III Gold
Packaging Extract from Agilent Technologies was used. This kit contained a lambda
phage extract, which would preferentially package DNA of around 40kb. Thus it was
ideal for use in our plasmid, which was 38kb. Two microliters of DNA containing either
the pE3.1+pE1.2 with luciferase, or pE3.1+pE1.2 with shRNA28, was added to the
extract and allowed to incubate for two hours at room temperature. At this point, 500 µL
of SM buffer, a lambda phage storage buffer, and 20 µL of chloroform were added to
the tubes. Tubes were spun down to sediment the debris, and the supernatant
containing the phage was decanted into a new tube and stored at 4 degrees until use.
VCS257 strain of E. coli from the Gigapack kit was plated overnight on LB agar.
A mini-prep from the resulting colonies was performed the next day in LB broth
containing 10 mM MgSO4 and 0.2% (w/v) maltose. This was grown at 37°C in a shaker
for six hours at 200 rpm. The bacteria were then pelleted at 500 x g for ten minutes and
resuspended to an OD600 of 0.5 with sterile 10 mM MgSO4 solution. 25 µL of each
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packaging reaction were added to 25 µL of cell suspension and incubated at room
temperature for 30 minutes. 200 µL of LB broth was then added to each sample, which
were then incubated for one hour at 37 degrees in a water bath to allow for antibiotic
resistance expression. Finally, these cells were spun down and resuspended in 50 µL of
LB broth. They were then plates on LB+Kanamycin and Ampicillin agar plates and
grown overnight.
Two colonies of each cosmid were observed the next day. A mini-prep for each
of these was performed using LB+kanamycin and ampicillin broth. The cosmids from
the cells were then purified using the Qiagen Midi Plasmid Purification kit. Analytical
digest using EcoRV as well as MluI enzymes on the purified cosmids confirmed the
correct identity of the cosmid.

Production and Recovery of rAd Virus

HEK 293 cells were grown on 6 cm cell culture dishes in 10 mL of Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 1X nonessential amino acids (NEAA), 2 mM glutamine, 100 units/mL of penicillin and 100 µg
/mL of streptomycin at 37˚C and 5% CO2. The cells were grown to 90% confluence
before the transfection.
In order to ensure proper adenovirus replication inside the HEK 293 cells, the
Luciferase and short hairpin 28 cosmids were digested with SwaI restriction enzyme.
SwaI digestion was used to linearize the cosmid for transfection, as adenovirus
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genomes can only be replicated in linear form. Three micrograms of DNA were digested
with 3 units of enzyme for one hour.
To transfect the cells with the purified digested cosmid, we used Lipofectamine
2000 from Life Technologies. First, 15 µL of lipofectamine were added to 250 µL of
antibiotic-free DMEM, and in a separate 1.5 mL centrifuge tube, 3 ug of cosmid DNA
were added to 250 µL of DMEM. These were allowed to sit for five minutes at room
temperature. Then they were combined, and incubated at room temperature for 30
minutes. During the incubation, the antibiotic containing media was removed from the
cell culture dishes. After incubation, the lipofectamine-DNA mixture was added to the
HEK 293 cells. 4 mL of antibiotic free DMEM was then added to the cells.

Purification of High Concentration Virus

Plates were monitored daily for signs of viral infection. In the case of adenovirus,
the hallmarks of infection (known as cytopathic effect, or CPE), include a refractive
edge, rounding, detachment and clumping into grape-like clusters. After 13 days, the
shRNA luciferase and BPTF shRNA lines showed CPE. When more than 30% of cells
had detached from their plates, the media and all cells were collected into a 15 mL
conical tube and spun down at 300 x g for 10 minutes. Roughly 20% of the media was
removed, and the pellet was resuspended in the remaining DMEM. The tubes were the
frozen in liquid nitrogen, and thawed at room temperature. This was repeated three
times for a total of four freeze-thaw cycles to release the virus from the cells. Finally, the
tubes were spun again to pellet cell debris and collect viral supernatant.
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The viral supernatant from the primary transfection was plated dropwise onto a
newly confluent 6 cm dish. This plate grew until CPE was observed and 30-50% of cells
detached. Then the viral supernatant was harvested again and plated onto a 10 cm
dish. The virus from the 10 cm dish was then plated onto three 10 cm dishes for a final
round of amplification.
The resulting cells were spun down, and resuspended in 3 mL of solution of PBS
with 10% glycerol. They were then frozen and thawed three times, spun down and the
supernatant containing the virus was aliquoted and frozen. This virus suspension was to
be used for intratumoral injections in mice.

Determination of Viral Concentration

Using a protocol obtained from OD260 (Boise, Idaho), the virus was assayed
with a Tissue Culture Infectious Dose 50 assay (TCID50). For each virus, one 10 cm
plate was seeded with HEK-HEK 293 cells in penicillin/streptomycin 10% FBS DMEM.
The confluent plates were trypsinized and collected into a 50 mL tube. This was spun
down at 300 x g for 10 minutes and the culture media was discarded. The pellet was
resuspended in 30 mL of DMEM.
Serial ten-fold dilutions were made of virus per Table 1.
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Virus
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103
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105
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109

1010
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90

90

90

90
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180

1080
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10 µL

10 µL

10 µL

10 µL

10 µL

10 µL

20 µL

120 µL

120 µL

120 µL

120 µL
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from

from

from

from

from

from

from

from

from

from

Dilution
DMEM
(µL)
Add:

10

10

10

10

10

10

10

10

10

1010

dilution

dilution

dilution

dilution

dilution

dilution

dilution

dilution

dilution

dilution

Pipet

Pipet

Pipet

Pipet

Pipet

Pipet

Pipet

Pipet

Pipet

Pipet

Pipet

in/out 4

in/out 4

in/out 4

in/out 4

in/out 4

in/out 4

in/out 4

in/out 4

in/out 4

in/out 4

in/out 4

x 90 µL

x 90 µL

x 90 µL

x 90 µL

x 90 µL

x 90 µL

x 180

x 1000

x 1000

x 1000

x 1000

µL

µL

µL

µL

µL

stock

Mix:

1

2

3

4

5

6

7

8

9

Table 1. Dilution scheme for TCID50 assay to determine viral titer. 10 µL of raw virus was
serially diluted by ten fold to achieve 10-8, 10-9, 10-10 and 10-11 concentrations of the undiluted
virus. These were plated with HEK 293 cells in replicates of 10 and observed for cytopathic
effect.

Using two 24 well plates for each virus, 10 replicates each of the 10-8, 10-9, 10-10
and 10-11 dilutions were added to each plate with two negative controls for each dilution.
100 µL of each viral dilution were added to each well, and 150 µL of HEK-HEK 293 cell
suspension were also added. To the negative controls wells 100 µL of DMEM were
added. After seven days the plates were monitored daily for CPE, which was noted as a
“positive” well. When the number of wells with signs of virus stabilized, the assay was
considered complete. The number of positive wells was entered into a spreadsheet
which used a formula given to us by OD260. The output of the formula was in
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TCID50/mL units, which correlates to roughly 1 plaque forming unit (PFU) per 0.69
TCID50. This was used to calculate virus concentration.

Confirmation of rAd Delivered shRNA KD Efficacy

In order to confirm that the created virus would knock down BPTF in mice, an in
vitro experiment was performed. 66CL4, 67NR, and 4T1 cells were plated at 20%
confluency on 6 cm dishes and 1 mL of concentrated viral supernatant were added and
allowed to incubate for three days. After three days, the plates were split 1:2 and again
1 mL of virus was added. One week after initial infection, the cells were collected with
Tri Reagent. 0.5 mL of Tri Reagent was added to each plate and the lysate was
collected into 1.5 mL microcentrifuge tubes. 100 µL of chloroform were added to each
tube of Tri Reagent and cells remnants. The tubes were spun at 21,000 x g for 5
minutes and the organic layer was transferred to a new tube. The proteins in the organic
layer were precipitated with 750 µL of isopropanol. The protein was pelleted by
centrifugation and resuspended in 0.3 M guanidine hydrochloride/95% ethanol solution
and allowed to wash overnight at 4°C. The next day the guanidine was removed and
replaced with 200 proof ethanol, and the proteins were again washed overnight. The
purified protein was washed with 70% ethanol and placed in 8M urea/1% SDS solution
at 65°C until dissolved.
The dissolved proteins were tested for concentration using a DC protein assay
and diluted to 2 mg/mL. 50 ug of protein from each cell line were loaded into 4% SDS
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gel. The proteins were transferred from the gel to a PVDF membrane by electrophoresis
at 20 V/ 30 mA for 17 hours. The membrane was blocked with 5% non-fat dry milk for
one hour, before anti-BPTF rabbit antibody was added at 1:5000 dilution and incubated
overnight at 4°C. The next day the membrane was washed once with PBST and then
placed in non-fat dry milk again, and incubated at room temperature for one hour with
horseradish peroxidase (HRP) linked anti-rabbit IgG at a dilution of 1:10,000. The
membrane was washed three times at room temperature on a rocker for 20 minutes
each. After washing the membrane was rinsed with luminol/ECL and exposed in a dark
room on film. Successful knock down was observed as a BPTF band of reduced
intensity.

Injection of rAd into Established Tumors

Mice were placed under 3% isoflurane and on a warm pad to maintain body
temperature for all injections. 4T1 cells were injected at 3x105 cells per 50 µL into the 4th
mammary fat pad of BALB/C mice. After 5 days, mice were injected with 1.2 mg
gemcitabine intra-peritoneally as per previously established lab protocols, and thereafter
given gemcitabine once a week. Mice were monitored three times a week for tumor
development. When the tumors reached 5mm in any direction, injections were initiated.
1x108 PFU of either virus were injected per day per mouse, three times a week
for three weeks. On injection days, tumors were measured by caliper before injection,
and tumor size was recorded.
After sacrificing the mice, tumors were excised. These were then weighed, and
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then ground up in a Trizol solution, and allowed to sit at room temperature for an hour.
To the Trizol suspension, 200 µL of chloroform was added for every mL of Trizol. After
vortexing, the suspension was spun at 12,000 x g for 15 minutes, and the red organic
layer was extracted. Proteins were precipitated with 1.5mL isopropanol for every mL of
Trizol, and the pellets were placed in 95% ethanol/guanidine hydrochloride overnight at
4°C. The next day the pellets were spun down and resuspended in 100% ethanol, and
once again placed on a rocker at 4°C overnight. The next day, pellets were washed in
70% ethanol and then placed in a 8M urea/1%SDS solution and heated at 65°C
overnight to dissolve the protein pellet.
Proteins were assayed by DC protein assay, and a Western Blot was performed
as described above to assess levels of BPTF in both the Luciferase and BPTF shRNA
treated tumors.

Isolation of Lymphocytes for Analysis by Flow Cytometry

At the end of their previously described incubation times, mice were sacrificed
and tumors were harvested. After weighing tumors and taking measurements, tumors
were sliced into 1 mm3 pieces. An enzyme mix consisting of 5 to 10 mL (5 mL for
tumors up to 100 mg, 10 mL for greater than 100 mg) HBSS salt solution, 1 mg/mL
collagenase type IV, 2% FBS and 0.4 mg/mL DNaseI was made, and the tumor slices
were placed in the mix. The digest was run for 30 minutes at 37˚C.
After digestion, tumor digests were run through a 40 µm mesh cell strainer (Life
Technologies), and the resulting solution was spun down at 300 x g for 10 minutes. The
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cells were resuspended in 40% Percoll, and a 70% Percoll layer was placed below
them. This solution was centrifuged at 3000 x g for 30 minutes. At the interface,
lymphocytes were collected and washed with PBS. The cells were spun down, and the
supernatant was discarded. The resulting pellet was resuspended in FACS buffer. The
cells were then split evenly into tubes for staining.

Flow Cytometry and Analysis of Tumor Infiltrating Lymphocytes

Lymphocytes isolated from the Percoll gradient were split into two tubes. One
tube contained 0.25 µg anti-NKp46 (FITC) and 0.1 µg anti-CD69 (PE), the other tube
contained 0.25 µg anti-NKp46 (FITC) and 0.25 µg anti-CD3e (PE). Cells were incubated
on ice for 20 minutes in the dark with the antibodies, then washed twice with FACS
buffer. Finally, all test samples were suspended in FACS buffer containing 0.5 µg of the
viability dye 7AAD.
For compensation controls, splenocytes were treated with red blood cell lysis
buffer for five minutes and then washed in order to obtain lymphocytes. These were
divided into four tubes; one unstained, one stained with 0.25 µg anti-CD8 (FITC), one
with 0.25 µg anti-CD3e (PE), and a tube containing 1 mg/mL 7AAD viability dye. These
were used to eliminate overlap in wavelengths between the two fluorescent signals of
FITC and PE, and any overlap between PE and 7AAD.
T-cells isolated from 4T1 adenovirus treated tumors were stained (per sample)
with 0.25 µg anti-CD8 (FITC) antibodies to identify T-cell populations, 0.1 µg anti-CD69
(PE) to measure activation, and 0.5 µg 7AAD to separate live from dead cells.
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IFN-γ Sample Preparation and ELISA

The night before harvesting, a 96 well plate was coated with capture antibody for
IFNg provided by the IFNg kit from Affymetrix. This was washed three times for one
minute each in PBST. Tumors from adenovirus injected mice were harvested the next
day. The tumors were minced into >1mm2 pieces and placed into an appropriate volume
of HBSS plus protease inhibitor. They were then frozen and thawed three times and
spun down at 21,000 x g for 15 minutes at 4°C. The supernatant was taken and the
protein concentration was measured by DC protein assay. Using a BSA standard curve,
all tumor samples were diluted to match the concentration of the least concentrated
tumor sample. 100 µL were loaded in triplicate along with an IFNg standard curve in
triplicate and allowed to incubate overnight at 4°C. The following day, the plate was
washed and blocked for one hour with assay diluent. Following this, it was washed
again and incubated with detection antibody. After an incubation of 1 hour at room
temperature, the plate was washed and then incubated with Avidin-HRP for 30 minutes.
Following the avidin step, the plate was washed seven times and 100 µL of TMB
solution was added for 15 minutes. Finally, stop buffer was added and the plate was
read at 450 nm for IFNg concentration by a spectrophotometer (Synergy H1 Multi-Mode
Plate Reader, BioTek).
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LDH Cytotoxicity Assay

Human tumor cells, both control and BPTF KD, were grown in a 6 well dish until
confluent. The day before the assay, these target cells were trypsinized, counted three
times for accuracy, and plated in a 96 well V-bottom dish at 5,000 cells per well, in
replicates of three per E:T ratio in experimental wells. In addition, wells were set aside
to compensate for maximum killing values and spontaneous release of LDH from
targets as well as effector cells.
The next day, NK-92 cells were added to targets at effector to target ratios of
2.5:1, 5:1, and 10:1. Once effector cells were placed on target cells, the plate was spun
down at 300 x g for five minutes and incubated at 37°C for four hours. 45 minutes
before adding substrate mix, lysis buffer was added to the maximum killing wells. At the
end of the four hour incubation, 25 µL of media was removed from each well, and to it
was added 25 µL of substrate mix. The plate was placed in the dark for 30 minutes at
room temperature. After incubating, 25 µL of stop solution was added to end the
reaction. The plate was then placed on a plate reader and the wells were read at 490nm
absorbance for LDH release by spectrophotometer (Synergy H1 Multi-Mode Plate
Reader, BioTek).

Statistical Analysis
Two tailed T-tests for significance between control and KD tumor weights were
performed on Microsoft Excel.
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Chapter 3: Results

Adenovirus Containing shBPTF Effectively Knocks Down BPTF in Established
Tumors; Tumor Growth is Inhibited.
Previous work in the Landry lab had shown that when cells were infected with a
short hairpin containing Lentivirus specific for BPTF, those cells grew less when
implanted in mice compared to controls. It was hypothesized that this anti-tumor effect
could be mirrored in an established tumor if an adenovirus were used to deliver the
BPTF shRNA.
In culture, BPTF was successfully knocked down in 4T1 (Fig. 13). For reasons
unknown, 67NR cells died after infection of rAd and thus could not be used for study.
After completing the production of the virus as described, mouse breast cancer line 4T1
was chosen as our model tumors based on the efficacy of the knock down in culture.
Throughout the 3 week growth period for 4T1, caliper measurements showed
decreased tumor volume in the knockdowns compared to controls (Fig. 14). After
excising them, tumor weights confirmed this trend. The knockdown virus in 4T1 tumors
resulted in a decrease of roughly 51% compared to luciferase hairpin containing virus
injected tumors (Fig. 15). Mean tumor weight for controls was .196 grams, compared to
.096 grams in knockdowns. Knockdown within the tumors was verified by Western Blot
(Fig. 16).
To confirm previous findings of increased T-cell activation and infiltration in BPTF
KD tumors, another set of mice (n=6) was used to investigate the T-cell infiltration and
activation of the 4T1 tumors by flow cytometry. Our results show that T-cells, while not
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more numerous, are more active in tumors treated with BPTF KD virus than controls
(Fig. 17).

BPTF KD Results in Increased IFNg Within the Tumor Microenvironment

Interferon gamma is a cytokine that has broad activity in activating lymphocytes,
and IFNg knockout mice have been shown to be highly vulnerable to carcinogenesis,
both in transplantable and endogenous cancers (Ikeda et al, 2002). To bolster our
hypothesis that lymphocytes are more active in BPTF KD tumors, we investigated rAd
treated tumors using the Affymetrix IFNg ELISA kit. As seen in Figure 18, a noticeable
(though not significant, p=.22) increase in IFNg was observed in the KD tumors, with an
average value of 632 pg/mL compared to 518 pg/mL in controls.

Figure 13. Western blot of control vs BPTF shRNA treated 4T1 cells in culture. 4T1 cells
were plated in 10 cm dishes and treated with either control or BPTF shRNA rAd for one week.
Protein was extracted using Tri Reagent and tested for BPTF levels using a Western Blot.
Ponceau S stain shows equal loading.
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Figure 14. Representative plot showing progression of tumor volume changes during rAd
treatment. 4T1 tumors that were treat with either control or BPTF shRNA virus were measured
with calipers on every injection day. Tumor volumes were calculated using V=π/6 (a*b2) where a
is the longest measurement and b is the shortest.
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Figure 15. BPTF KD in 4T1 results in reduction of tumor mass. 4T1 tumors treated with
either control (n=5) or BPTF KD (n=6) rAd were harvested and weighed. The mean weight of
control tumors was .196 g, compared to a mean weight of .096 g for KD.
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Figure 16. BPTF is knocked down by rAd in established tumors. Western Blot showing
BPTF knockdown in tumors injected with shBPTF rAd. Ponceau S stain confirmed equal
loading.
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Figure 17. Flow cytometry shows an increase in T-cell activation in BPTF KD tumors.
Flow cytometry was performed on four (two control, two KD) 4T1 tumors treated with
recombinant adenovirus. A.) Gating strategy shows the lymphocyte population from which Tcells were selected. B.) Representative plot from a control tumor showing CD8 vs CD69 T-cell
activation. C.) Percentages of TIL CD8+ population in control and KD. D.) Significant (p<.05)
increase in active T-cells in BPTF KD tumors.
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Figure 18. BPTF KD Tumors Show a Slight Increase in IFNg Secretion. An increase was
seen in IFNg secretion from BPTF KD tumors (n=4), with an average of 632 pg/mL compared to
controls (n=3), which had an average of 518 pg/mL.

NK Cells in 66CL4 and 67NR are More Active in BPTF KD Tumors

Our previous studies showed increased NK cell mediated anti-tumor immunity to
BPTF KD 66CL4 and 67NR BPTF KD tumors. We next sought to confirm whether there
was increased NK cell infiltration or activity in these tumors. Towards this end,
lymphocytes harvested from 66CL4 and 67NR tumors were assayed by flow cytometry
to measure NK infiltration and activation. To measure infiltration, CD3 and NKp46
antibodies were used. CD3 is found on T-lymphocytes and is required for T-cell
activation. It is not found on NK cells. Conversely, NKp46 is an activating receptor found
exclusively on NK cells. Using these two stains allowed us to separate T cells from NK
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cells, as seen in our gating strategy (Fig. 19). We found no significant difference
between control and KD in NK infiltration (Fig. 20).
To measure activation, we once again employed anti-NKp46 to identify NK cells,
as well as anti-CD69 staining to measure activity. CD69 is an early activation marker
found on T-cells and NK cells. We found that there was a slight increase in the
activation of infiltrating NK cells in 67NR KD tumors. There was, however, a statistically
significant increase (p<.05) in activation of infiltrating NK cells in BPTF KD in 66CL4
tumor lines (Fig. 21). On average, 66CL4 BPTF KD cells had 48 and 44% active NK
cells for short hairpins 1 and 2, respectively. This is 19 to 23 percent greater than the
control, which had an average of 25% activated NK cells.
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Figure 19. Gating strategy for 66CL4 and 67NR flow cytometry. CD3Neg,NKp46+ populations
(above) were gated to measure activation (below) in 67NR and 66CL4 using CD69 as an
activation marker. 4T1 tumors were used as a control for the staining method.
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Figure 20. Flow cytometry results show no difference in NK cell infiltration between
control and BPTF KD tumors. Level of infiltration was assessed by flow cytometry using NK
cell specific anti-NKp46 (FITC) and T-cell specific anti-CD3 (PE) antibodies. Infiltration of NK
cells in 66CL4 and 67NR tumors showed no significant difference between control and KD.
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Figure 21. BPTF KD show increased T-cell activation by flow cytometry. Anti-NKp46
(FITC) and anti-CD69 (PE) stains were used to measure activation of T-cells in 66CL4 and
67NR tumors. Greater activation of NK cells was seen in 66CL4 to a statistically significant
degree KD lines. Statistical significance was not met for the increase in 67NR. * = p-value <.05
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NK-92 Cells Preferentially Kill BPTF KD Cells in T47D and MDA-436 Lines

Our hypothesis as to how BPTF KD aids in tumor clearance involves either an
upregulation of cell stress (stimulatory) surface ligands, or a downregulation of inhibitory
ligands. Therefore, it followed that NK cells would recognize these cell surface changes
and kill BPTF KD cells more effectively than controls. To test this, we measured for
increased killing of BPTF KD tumor cells compared to controls by NK cells using
Promega’s Cytotoxicity kit. This assay involves plating a number of target cells, then
incubating them with NK effector cells and then assaying for released LDH. The amount
of LDH correlates with cell death.
The NK cells used in these studies were an immortalized NK cell line known as
NK-92. These cells are derived from a patient who had non-Hodgkins lymphoma. They
are known for their high cytotoxicity compared to other NK lines and can be grown
easily in a lab to great numbers (Tam et al, 2003). Additionally, they are being
investigated for clinical use in cancer patients (Cheng et al, 2013), so their use in these
studies lends further credibility to the therapeutic applications of BPTF KD.
For targets, we chose two cell lines that had previously been treated with a short
hairpin containing retrovirus to KD BPTF; T47D (Figure 22), a human breast cancer cell
line, and MDA-MB-436, another human breast cancer line. We used a 10:1 effector-totarget (E:T) ratio, as below 10:1 killing could not be observed. Our results show at 10:1
ratio T47D KD cells were killed in greater numbers than control cells (Fig. 23). The
negative percent cytotoxicity from the control line can be attributed to little cell death but
spontaneous release of LDH creating background. MDA-436 showed increased killing
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as well, however the second BPTF short hairpin was highly variable (Fig. 24).

Figure 22. Western Blot of BPTF KD human breast cancer line T47D. Human breast cancer
line T47D was used to test effect of BPTF KD on human NK cell cytotoxicity. Lentivirus was
used to introduce either a control shRNA or BPTF shRNA into T47D cells. Western blot
confirmed KD of BPTF with both hairpins. Ponceau S stain was used to assess equal loading.
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Figure 23. BPTF KD T47D cells are killed in greater numbers than controls. Using NK-92
effector cells at a ratio of 10:1 to target cells, cytotoxicity assay results show BPTF KD cells are
killed more effectively than control.
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Figure 24. BPTF KD MDA-MB-436 cells are also more readily killed by human NK-92 cells.
Preliminary data from cytotoxicity assay using human breast cancer cell line MDA-436 at an E:T
ratio of 10:1. BPTF KD lines were killed in greater numbers (p=.053 for sh1, p=.87 sh2) than the
control.
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Chapter 4: Discussion

Epigenetic abnormalities can be found in every type of cancer (Jones & Baylin,
2002). Among them, disrupted chromatin organization is found in virtually every known
cancer type (Jones, Baylin 2007). For instance, the well-known tumor suppressor
protein Rb (retinoblastoma) works to deactivate cell cycle genes by recruiting enzymes
which deacetylate histones, rendering promoters inaccessible (Wolffe, 2001). When Rb
is mutated, these genes go unchecked and malignancy ensues.
Mounting evidence supports the role that ATP-dependent chromatin remodeling
complexes play in tumorigenesis (Wang et al, 2007. Bochar et al, 2000.) Given that
chromatin reactions are reversible, they make ideal targets for therapy, as this would
theoretically yield a better safety profile than traditional chemotherapeutics (Mayes et al,
2014).

BPTF KD Results in Dramatic Tumor Reduction in Established Tumors
The results from my adenoviral studies showed that in established tumors of
equal initial size, BPTF knockdown resulted in a near significant (p=.06) reduction of
mass by half, and more replicates will likely bring this result to statistical significance. It
should be noted that most studies using intratumoral recombinant adenovirus use titers
between three and tenfold higher or more than the one used in this work (Miller et al,
2004. Jung et al 2014. Chao et al, 2014). Dose response studies using higher viral
concentrations may well reveal a more dramatic effect on tumor size in the future.
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As the studies presented here show, the immune system is intimately involved in
the clearance of BPTF KD cells. Previous work in the Landry lab indicated an
upregulation of Lmp and Tap genes in 4T1 BPTF KD tumors (Mayes et al, in revision,
Cancer Research). These genes are responsible for the creation of antigen processing
molecules, which transport MHC class I molecules to the cell surface. This is important
in the context of CTL mediated cancer cell killing. Cells which are able to avoid CTL
killing often downregulate their Tap and Lmp expression, in order to limit T-cell
recognition by MHC-I. Therefore when BPTF KD cells upregulate the delivery of MHC
class I antigens to their cell surface, they become more antigenic, which leads to
greater activation of lymphocytes and production of IFN-gamma. These results are
consistent with the observations from each of my studies.

Increased IFNg in the Tumor Microenvironment of BPTF KD Tumors

My results suggest that IFNg is increased in BPTF KD tumors relative to controls,
although more experiments will be needed to achieve statistical significance. IFNg is a
cytokine that regulates both innate and adaptive immune responses (Young and Hardy,
1995). Produced by NK cells and T-cells (and NK-T cells) it has been shown to be
closely involved in the anti-tumor response from lymphocytes. In a study by Kaplan et
al, mice which had had their receptors to IFNg knocked out grew tumors more rapidly
and aggressively than their immunocompetent wild-type counterparts. Other studies
have shown that increased intratumoral IFNg was associated with a reduction in tumor
mass (Nastala et al, 1994).
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When IFNg is secreted, it has a number of effects on immune cell function and
differentiation. IFNg has been found to directly affect the differentiation of CD4 cells by
promoting TH1 helper T cell development and inhibiting TH2 development (Bradley et al,
1996.) The consequences of increased TH1 differentiation is increased IFNg IL-2
secretion, recruitment of macrophage cells, and elevated IL-12 production (Montovani et
al, 2002). IL-12 could further stimulate NK cell, CTL, and antigen presenting cell (APC)
activity, as well as proliferation of said cells, which in turn would produce IFN-g
(Trinchieri 1995). Taken together, this forms a feedback system where more anti-tumor
effector cells are activated in the tumor which potentially inhibit tumor growth.
One of the downsides of increased production of IFNg is that it also promotes
infiltration by myeloid derived suppressor cells, or MDSCs (Zaidi et al 2011). These cells
suppress T-cell activity by secreting reactive oxygen species, arginase and nitrous
oxides (Gabrilovich et al 2010.) It is possible that in our studies with 4T1, the
disadvantages of increased IFNg associated with MDSC infiltration were eliminated by
our use of gemcitabine, a drug used to deplete MDSC growth (Le et al, 2009). My
studies on 66CL4 and 67NR tumors by flow cytometry indicate a possible granulocyte
population (data not shown), which contrasts the distinct lack of granulocytic cells in
flow cytometry results in 4T1. One reason that tumor growth inhibition in 66CL4 and
67NR is mediated by NK cells and not by CTLs could be because of the presence of an
MDSC population. In future studies concerning 67NR and 66CL4, an ELISA based
assessment of IFNg levels in BPTF KD tumors will likely find that IFNg is elevated.
MDSC populations would then be identified by flow cytometry using anti-Gr1 and antiCD11b staining as done by Youn et al. Once it has been established that there is a
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population of MDSC in 67NR and 66CL4, MDSC depletion studies using gemcitabine
could potentially increase the anti-tumor effects of BPTF KD in 67NR and 66CL4, and
should be investigated further.

Flow Cytometry Reveals Role of Immune System in BPTF KD Tumor Growth
Inhibition

The increase in IFNg in BPTF KD 4T1 tumors suggests that KD of NURF is a
driver of heightened lymphocyte activation. Flow cytometry results provide support for
this idea by showing a repeated trend of increased activation in both NK cells and Tcells. NK cell infiltration, however, was not elevated in 66CL4 and 67NR BPTF KD
tumors as we had previously seen with the T-cell studies using 4T1 and B16F10. A
possible explanation for this is the difference in clonal expansion and proliferation
between NK cells and T-cells. Once activated in the spleen, different T-cell populations
which are primed by multiple antigens will expand 1,000 fold over the week following
their activation. By contrast, studies have shown that NK-cells, which do not need to be
activated by specific antigens, increase in number by only 10-15 fold (Raulet, 2004).
Therefore a difference in infiltration does not necessarily diminish the repeated and
significant findings of increased activation of lymphocytes in BPTF KD tumors.
These results confirm that something within the NURF KD tumor
microenvironment is eliciting a heightened response from NK cells and CTLs, as seen
from multiple studies on different tumor lines. It is likely that BPTF KD causes a
downregulation of inhibitory signals on the cell surface, or an upregulation of stimulatory
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ligands to these effector cells. It is more probable, however, that upregulation of
stimulatory ligands are responsible for tumor inhibition, as our LDH studies indicate.
This in turn leads to greater recognition and killing of BPTF KD cells by lymphocytes.

Cytotoxicity Results with Human Cells Yield Glimpse of Therapeutic Benefit

To test whether the advantage BPTF KD provides in killing tumors is conserved
in humans, the human cell lines T47D and MDA-MB-436, both breast cancer lines, were
assayed using NK-92 cells. NK-92, an immortalized NK cell line, is very useful in
cytotoxicity assays on tumors because it has high killing capabilities. To affect these
responses it has very few inhibitory receptors, but maintains virtually all of the native
activating receptors found on NK cells (Tonn et al, 2001). Given that there are almost no
inhibitory receptors on NK-92 cells, the mechanism by which BPTF KD cells promote
NK cell activation likely lies in the improved presentation of stimulatory ligands. This
limits the recognition of BPTF KD cells to a handful of NK receptors: NKG2D, NKG2E,
2B4, NKp30, NKp46, and CD28 (Tonn, 2001). Many of these receptors are well studied
and their ligands are known and largely characterized.
To characterize the effects of a NURF KD on anti-tumor immunity, we must first
identify by which receptor NK cells are activated to kill BPTF KD tumor cells. Thanks to
the well-characterized nature of the NK-92 receptors, the search for likely NK receptors
important for enhanced killing of BPTF KD cells has narrowed considerably. To do this,
there are several tools at our disposal: antibody based blocking of the receptors
(Perussia et al, 1983. Bauer et al, 1999), competitive inhibition of the substrate
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(Bloushtain et al 2004), or shRNA knockout of the receptors in NK-92. An shRNA
knockdown is feasible, albeit more time consuming. The easiest of these strategies is
likely a competitive inhibition based approach. Using known ligands of each NK receptor
in the presence of both BPTF KD and control, we could then assess the effect on killing
by cytotoxicity assay. If a specific ligand for an NK receptor is found to reduce BPTF KD
killing, an antibody blocking experiment should be used to confirm the identity of the
receptor.
Once a receptor has been identified, the hunt then begins for a ligand. Many of
the activating receptors on NK cells have known and well characterized ligands (Lanier
1998. Bottino et al, 2005). Given that NURF is known to occupy promoter sites for
transcriptional activation, it is quite plausible that in cancer, amplification of NURF leads
to overexpression of a protein that functions to inhibit the cell surface presentation of an
stimulatory NK-cell ligand. In the future, microarray data could be used to see changes
in expression patterns of known NK cell receptor ligands.
Our studies have shown in the preliminary cytotoxicity data that the method of
killing seen in the mouse model is potentially conserved in humans. The LDH assay
used is prone to high intra-assay variability due to the background that is given off by
these cell lines. More experiments will be needed before a definitive interpretation of the
data is established. If further studies confirm these initial LDH data in human cells, it
would represent a step forward in making the case for a new class of drug, as animal
models alone often do not translate to clinical success (Pound and Bracken, 2014.)
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Therapeutic Potential of BPTF Targeting

The Holy Grail of cancer treatment is a targeted drug agent which limits collateral
damage to healthy cells such as the kind seen in traditional chemotherapy and radiation
regimens, while selectively killing tumor cells. The work presented in this thesis
represents a proof of concept for a new drug. Adenoviruses are not a viable delivery
vehicle for therapeutic molecules. They elicit too strong an immune response and can
return to a replicative state, as seen in a patient who died after gene therapy in 1999
(Marshall 1999), which cuts into idea of a safer treatment than conventional cancer
treatment. It may be possible for the results in this paper to translate to a gene therapy
using adeno-associated virus. This is a vector which in recent years has seen increased
use due to its low pathogenic potential but high rate of delivery for interfering RNA
(Daya et al, 2008). However, the last 15 years have given way to a new class of antitumor medication as small molecule inhibitors have emerged as a viable option for
targeted cancer treatment. Small molecule inhibitors have been used extensively in
recent years to combat cancer.
The most well-known example of a small molecule inhibitor is imatinib, a tyrosine
kinase inhibitor used to treat chronic myelogenous leukemia (Hoelder et al, 2012).
Tyrosine kinases deregulated in cancer cause unchecked cell growth and proliferation
(Paul et al, 2004). For reasons unclear, a mutation in these patients causes constitutive
expression of TKs, leading to malignancy.
TK inhibitors success lies in the fact that so many cancers de-regulate tyrosine
kinase activity. Likewise, BPTF has been found to be highly expressed many different
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tumor tissues (Buganim et al, 2010.) As we have shown here, unlike TKs which give a
proliferative advantage, BPTF represents a different tumor growth tactic: evasion.
A small molecule inhibitor of BPTF, perhaps one that competes for its SNF2L
domain with ATP (taking cue from TK inhibitors), would allow the patient’s own immune
system to take over. It would also help as a second line treatment for kinase inhibitor
resistant diseases, which due to the adaptive nature of cancer cells, may require
combination drug therapy (Weinstein and Joe, 2006. Holohan et al, 2013). Future
studies on BPTF knockdown by virus should not only utilize dose-response experiments
as mentioned above, but also consider adenoviral treatment plus epigenetic based
cancer drugs such as histone deacetylase inhibitors to observe the extent of remission
that can be achieved.
The work presented in this thesis is the first to show that knockdown of BPTF in
established primary tumors can reduce tumor growth. Along with the future studies
suggested in this paper, a strong case can be put forth to develop a NURF inhibitor as a
new class of cancer treatment.
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